ALVR AlloVir

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at .

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit or follow us on or .

EN
16/11/2023

Underlying

ALVRAlloVir

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlloVir

 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris and AlloVir Announce Stockholder Approval of Merger

Kalaris and AlloVir Announce Stockholder Approval of Merger Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders ...

March 12, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir and Kalaris Therapeutics Announce Agreement for Transformation...

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and could potentially provide a meaningful a...

November 8, 2024 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir Provides Updates on Phase 3 Clinical Development Program for P...

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. ...

December 22, 2023 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Confere...

WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET. A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at . About AlloVir AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural ...

November 16, 2023 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir Reports Third Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30, 2023. AlloVir continues to progress its highly innovative lead therapeutic candidate, posoleucel, by enrolling globally in three Phase 3 trials for first-to-market indications. AlloVir is in a position of strength with significant financial resources to support operations through topline data readouts for all three trials anticipated in the second half of 2024. “At AlloVir, we are dedicated t...

November 2, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch